Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360481/
https://www.ncbi.nlm.nih.gov/pubmed/35652222
http://dx.doi.org/10.1158/2159-8290.CD-22-0365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360481/
https://www.ncbi.nlm.nih.gov/pubmed/35652222
http://dx.doi.org/10.1158/2159-8290.CD-22-0365

Ejemplares similares